Impact of Brokerage Rating on Portola Pharmaceuticals, Inc.(PTLA)

Many Portola Pharmaceuticals, Inc.(PTLA) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Portola Pharmaceuticals Inc was Upgraded by Citigroup to Buy on Jan 3, 2017. Company shares were Reiterated by Credit Suisse on Dec 27, 2016 to Outperform, Raises Price Target to $ 29 from a previous price target of $20 .

Company has reported several Insider transactions to the SEC, on May 3, 2016, William Lis (Chief Executive Officer) sold 5,675 shares at 23.86 per share price.On Sep 21, 2015, Mardi Dier (Executive VP and CFO) sold 8,912 shares at 55.00 per share price.On Sep 18, 2015, Charles J Homcy (director) sold 40,067 shares at 56.25 per share price.

Portola Pharmaceuticals Inc Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-1.61 EPS for the quarter, missing the analyst consensus estimate by $ -0.49. Analyst had a consensus of $-1.12. The company had revenue of $9.30 million for the quarter, compared to analysts expectations of $4.16 million. The companys revenue was up 220.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.05 EPS.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.83 by 3 Brokerage Firm. 1 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 1 Brokerage Firms have advised hold.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) stock has received a short term price target of $ 32.33 from 3 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $6.66. The higher estimate of target price is $40 , while the lower price target estimate is $28

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rose 0.46% or 0.14 points on Tuesday and made its way into the gainers of the day. After trading began at $30.06 the stock was seen hitting $30.78 as a peak level and $29.62 as the lowest level. The stock ended up at $30.29. The daily volume was measured at 1,371,605 shares. The 52-week high of the share price is $33.28 and the 52-week low is $15.68. The company has a market cap of $1,713 million.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.

Portola

For any feedback and suggestions contact author at Ryan.Silvi@thefoundersdaily.com

Add Comment